Navigation Links
Signalife to Issue Breaking News Regarding Vianale & Vianale Tomorrow
Date:9/2/2008

LOS ANGELES, Sept. 2 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN) announced earlier today that breaking news will be issued tomorrow, at the opening of the market, regarding the law firm of Vianale & Vianale, and others.

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices, therapies and/or technologies that simplify and reduce the costs of cardiovascular disease.

Signalife, Inc. is traded on the American Stock Exchange under the symbol SGN. More information is located at http://www.signalife.com. Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause the companies' actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating the companies' technology procure market acceptance for these products, failure to obtain federal or state or governmental or international regulatory approvals governing heart monitoring and other biomedical devices incorporating the technology, failure to obtain import and export capabilities in the various countries containing buyers and resellers and hospitals and clinics and doctors for the devices, inability to obtain physician, patient or insurance acceptance of or for heart monitoring and other biomedical incorporating of the technologies, and the unavailability of financing to complete management's plans and objectives, including th
'/>"/>

SOURCE Signalife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
2. AFL To Return to Oklahoma Due to Overwhelming Demand for Signalife Heart Screening
3. Signalife Board Approves Merger
4. Signalife Announces AFL Joins NIH Education Program
5. Signalife Appoints Lee Ehrlichman President and Chief Operating Officer
6. Signalife Appoints Lee Ehrlichman as Company Director and Operations Director; Additional Notice Received From Amex Regarding Sharholders Equity Deficiency
7. Signalife Awarded New U.S. Patent, System For, And Method Of, Monitoring Heartbeats Of A Patient
8. Signalife Announces Webcast
9. AMEX Notifies Signalife That It Has Accepted Signalifes Plan of Compliance
10. Signalife Sees Accretive Purchase and Financial Commitments
11. Signalife Wins Second Frost & Sullivan Technology Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... ... to market the TriPollar Technology- the most advanced 3rd generation Radio Frequency ... been clinically proven the world over to be safe and effective on ... enjoy visible results from the very 1st treatment. Long term results ...
... ... Ingelheim today announced results from the RE-COVER(TM) study investigating dabigatran etexilate ... warfarin in patients with acute VTE. Results of the trial ... and simultaneously published online in the New England Journal of ...
... , , Alberta Centre for Advanced ... & medical seminar, , EDMONTON, Dec. 4 /PRNewswire/ - Today ... like nanotechnology, biomaterials and microfluidics can play a powerful role ... health and improve the quality, cost and outcomes of patient ...
Cached Biology Technology:Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Alberta companies delivering new products to the health & medical marketplace 2
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ... 2015-2019"  report to their offering. ... advances in technology. With continuous advances in technology, ... the latest standard that meets the needs and ...
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences ... monitoring, has released a new series of digital ... preclinical toxicology researchers. M series, part of the ... collect the best possible physiologic data when incorporating ... Adding functional endpoints to toxicology studies has evolved ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical ... building for its School of Medicine. Funding for this ... capital campaign that will be publicly launched next summer. ... located in the former 60 series R.J. Reynolds Tobacco ... Quarter. Construction will begin immediately with plans to be ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... or persistent seizures into a medically induced coma currently ... monitor the patient,s brain activity and manually adjust drug ... Now a computer-controlled system developed by Massachusetts General Hospital ... more precise and efficient and opening the door to ...
... bad thing, but experiments by researcher Peter Chien and ... Amherst recently showed that for the bacteria Caulobacter ... is required to keep it alive. DNA ... processes in all organisms, says Chien, an assistant professor ...
... Mich. Researchers from the University of Michigan Comprehensive ... function of critical immune cell subsets called T-cells, which ... effect of lifesaving bone marrow transplants. These new ... T-cells help fight infections but also can trigger autoimmune ...
Cached Biology News:Automated system promises precise control of medically induced coma 2Automated system promises precise control of medically induced coma 3Biochemists find incomplete protein digestion is a useful thing for some bacteria 2Newly identified proteins make promising targets for blocking graft-vs.-host disease 2
... deparaffinize and perform Heat Induced Antigen Retrieval ... mounted on glass microscope slides. Deparffinization is ... high temperature used in HIER (over 90degrees ... by detergent. Formaldehyde fixation impairs or totally ...
... Bovine Calf Serum; U.S. ... seek an uncompromising quality; Low ... Collected from animals of US ... those who seek an uncompromising ...
Collected from animals of U.S. origin.Collected from animals of U.S. origin. *Can be used in cell growth studies and immunoassays. *Sterility tested, * Mycoplasma tested upon request, *Endoto...
...
Biology Products: